DOV Pharmaceutical, Inc. is a biopharmaceutical company historically focused on the development of novel product candidates for disorders of the central nervous system. The Company has previously funded drug development programs that are now at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947, DOV 102,677 and a preclinical discovery program in reuptake inhibitors and GABA modulators. The Company operates on a very limited basis and is focused on soliciting interest in the sale or license of the Company’s business and assets, either as a single entity or in a series of transactions.
CSRHub includes data on Environment, Sustainable Development Goals, International Integrated Reporting Council, Sustainability reporting, Employees, and current environmental issues.